7ZT Stock Overview
Engages in the development of drugs for the treatment and prevention of cancer in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Hamlet BioPharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.33 |
| 52 Week High | SEK 0.41 |
| 52 Week Low | SEK 0.30 |
| Beta | 1 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 455.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7ZT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.3% | -3.0% | -0.1% |
| 1Y | n/a | -19.4% | 2.3% |
Return vs Industry: Insufficient data to determine how 7ZT performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 7ZT performed against the German Market.
Price Volatility
| 7ZT volatility | |
|---|---|
| 7ZT Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 7ZT has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 7ZT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 7 | Petter Lindqvist | www.hamletpharma.com |
Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company’s products under development include Alpha1H for the treatment of bladder cancer and brain tumors; and BAMLET for the treatment of colon and oral cancer.
Hamlet BioPharma AB (publ) Fundamentals Summary
| 7ZT fundamental statistics | |
|---|---|
| Market cap | €61.18m |
| Earnings (TTM) | -€2.94m |
| Revenue (TTM) | €208.63k |
293.3x
P/S Ratio-20.8x
P/E RatioIs 7ZT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7ZT income statement (TTM) | |
|---|---|
| Revenue | SEK 2.37m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 2.37m |
| Other Expenses | SEK 35.78m |
| Earnings | -SEK 33.41m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 28, 2024
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,410.60% |
| Debt/Equity Ratio | 0% |
How did 7ZT perform over the long term?
See historical performance and comparison